Amgen announced a 58% drop in the risk of death. The drug is Imdelltra. The partner is AstraZeneca's Imfinzi. The setting is extensive-stage small cell lung cancer.
Median survival hit 21.1 months versus 12.7 months on Imfinzi alone. Nearly 80% of patients were alive at one year, against 53%. Progression-free survival went from 1.9 months to 7.4.
Real numbers. Real people. Real months with real family.
Now compare that to your portfolio.
You will read this headline, open a brokerage app, and buy Amgen call options expiring Friday. You will call this "doing research." The research was a headline.
The trial data went to the European Society for Medical Oncology Congress. It did not go to your Discord server. Nobody there will read a hazard ratio of 0.42. Most of them think a confidence interval is a type of bank loan.
Amgen's own press release called the result "unprecedented." Wall Street already priced in the optimism, the trial design, and probably the weather in Thousand Oaks. You arrived last, as usual, holding a limit order and a feeling.
The combo has a cost. Grade 3 or higher adverse events hit 20.9% of patients, versus 10.8% on Imfinzi alone. Medicine comes with side effects. So does day trading. Yours include rent.
AstraZeneca built Imfinzi. Amgen built Imdelltra. Two giant companies put their drugs together and bought patients time. You put two indicators together on a chart and bought a lesson.
The patients got eight extra months. You got a margin call and a nickname in the group chat.
Photo by on Unsplash
Leave a Comment